Market research
NATCOPHARM.NSE NATCO Pharma Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 145B
- P/E ratio
- 12.47
- Analyst target
- 1004.4445
- Dividend yield
- 0.6%
- Beta
- 0.15
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE987B01026
- Market cap
- 145B
- P/E ratio
- 12.47
- Analyst target
- 1004.4445
- Dividend yield
- 0.6%
- Beta
- 0.15
About
About NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Research context
NATCO Pharma Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NATCOPHARM.NSE discussion.
5 years, 6 months ago
NATCO Pharma Limited is currently in a long term uptrend where the price is trading 14.5% above its 200 day moving average.
From a valuation standpoint, the stock is 48.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.1.
NATCO Pharma Limited's total revenue sank by 26.3% to $4B since the same quarter in the previous year.
Its net income has dropped by 40.0% to $627M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.9% to $2B since the same quarter in the previous year.
Based on the above factors, NATCO Pharma Limited gets an overall score of 2/5.